ChemicalBook > CAS DataBase List > Pazopanib-d6

Pazopanib-d6

Product Name
Pazopanib-d6
CAS No.
1219592-01-4
Chemical Name
Pazopanib-d6
Synonyms
Pazopanib-d6;2H6]-Pazopanib;2-methyl-5-[[4-[methyl-d3-[3-methyl-2-(methyl-d3)-2H-indazol-6-yl]amino]-2-pyrimidinyl]amino]-benzenesulfonamide;2-methyl-5-({4-[(2H?)methyl[2-(2H?)methyl-3-methyl-2H-indazol-6-yl]amino]pyrimidin-2-yl}amino)benzene-1-sulfonamide
CBNumber
CB72741889
Molecular Formula
C21H23N7O2S
Formula Weight
437.52
MOL File
1219592-01-4.mol
More
Less

Pazopanib-d6 Property

storage temp. 
Store at -20°C
solubility 
DMF: 16 mg/ml; DMSO: 16 mg/ml
form 
A solid
color 
White to off-white
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
25446
Product name
Pazopanib-d6
Purity
≥99% deuterated forms (d1-d6)
Packaging
500μg
Price
$290
Updated
2024/03/01
Cayman Chemical
Product number
25446
Product name
Pazopanib-d6
Purity
≥99% deuterated forms (d1-d6)
Packaging
1mg
Price
$549
Updated
2024/03/01
AK Scientific
Product number
3396DH
Product name
2-Methyl-5-[[4-[[3-methyl-2-(trideuteriomethyl)indazol-6-yl]-(trideuteriomethyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide
Packaging
1mg
Price
$710
Updated
2021/12/16
More
Less

Pazopanib-d6 Chemical Properties,Usage,Production

Description

Pazopanib-d6 is intended for use as an internal standard for the quantification of pazopanib by GC- or LC-MS. Pazopanib is a multi-kinase inhibitor that inhibits the VEGF receptors VEGFR1, VEGFR2, and VEGFR3 (IC50s = 10, 30, and 47 nM, respectively, in a cell-free enzyme assay).1 It also inhibits PDGFRα, PDGFRβ, and c-Kit (IC50s = 71, 84, and 74 nM, respectively, in a cell-free enzyme assay) as well as additional receptor tyrosine kinases. Pazopanib inhibits upregulation of the surface adhesion proteins ICAM-1 and VCAM-1 induced by VEGF in multiple myeloma cells cocultured with human umbilical vein endothelial cells (HUVECs) and decreases multiple myeloma cell adhesion to HUVECs.2 It also inhibits proliferation of multiple myeloma cells cocultured with HUVECs. Pazopanib (30 and 100 mg/kg) reduces tumor growth, induces apoptosis, decreases angiogenesis, and increases survival in a multiple myeloma mouse xenograft model. Formulations containing pazopanib have been used in the treatment of cancer.

References

1. Kumar, R., Knick, V.B., Rudolph, S.K., et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity Mol. Cancer Ther. 6(7),2012-2021(2007).
2. Podar, K., Tonon, G., Satler, M., et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma Proc. Natl. Acad. Sci. USA 103(5),19478-19483(2006).

Pazopanib-d6 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Pazopanib-d6 Suppliers